as high as 70.1% after a median follow-up of 48 months. 17 Studies in each larenotide group remain difficult to compare because of various remission criteria, various treatment times, different dosages, pre-selection bias, baseline GH and IGF-I levels, pituitary tumour size, whether lanreotide was used as primary or adjunctive therapy and, last but not least, variability of GH and IGF-I assays. In their review on therapy of acromegaly with lanreotide, Roelfsema et al. 7 collected data from 10 studies using lanreotide Autogel. In seven of these studies the number of successfully age-adjusted IGF-I levels varied in a close range between 48 and 55%.
Biochemical Efficacy of Lanreotide Autogel Versus Octreotide LAR
A number of studies have been carried out to compare the biochemical efficacy of octreotide LAR and lanreotide SR, but prospective randomised studies are lacking. In two meta-analyses 18, 19 of these results it was concluded that the biochemical efficacy of octreotide LAR was moderately more efficacious than lanreotide SR.
Five studies have compared the efficacy of octreotide LAR and lanreotide Autogel in a total of 74 patients. 15, [20] [21] [22] [23] The results were analysed by Murray and Melmed. 19 The studies suggested that lanreotide Autogel and octreotide LAR were equivalent in the control of symptoms and biochemical markers in patients with acromegaly.
In one of these studies 23 of the 10 patients who completed the study, four had normalisation of IGF-I levels on both therapies, but three patients had different treatment responses with biochemical normalisation during one therapy and not the other. Consequently, the change from octreotide LAR to lanreotide Autogel or vice versa may be useful in some patients with treatment failure or side effects.
Effects of Lanreotide

Glucose Homeostasis
GH excess in acromegaly is frequently associated with insulin resistance and impaired glucose tolerance as well as the development of diabetes.
These disturbances may be in part responsible for the increased cardiovascular morbidity and mortality associated with acromegaly.
Reports on the effects of somatostatin analogues on glucose homeostasis have given contradictory results. 24 Most of these studies involved only small numbers of patients and did not evaluate glucose metabolism as the main clinical end-point. A recent meta-analysis by Mazziotti et al. 25 concludes that the effects of somatostatin analogues on glucose homeostasis generally only have a marginal clinical impact, even when significant deleterious glycometabolic effects may be observed in some patients. Consequently, glycometabolic follow-up needs to be carefully carried out in patients with acromegaly. In pooled data of 332 patients, treatment-related abnormalities in glycaemic control (hyperglycaemia, hypoglycaemia and diabetes) occurred in 7%.
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The meta-analysis 25 demonstrates that somatostatin analogues decrease fasting serum insulin levels without consistent effects on glucose homeostasis. Some impairment of glucose metabolism was observed early after starting treatment, becoming less important as therapy progressed. 26 The decrease in insulin levels may have been caused by suppression of insulin secretion with somatostatin analogues, but the prevailing cause is usually the decrease of insulin resistance with normalisation of GH and glucagon secretion.
Consequently, lack of growth hormone control may predispose to a worsening of glucose metabolism.
The meta-analysis shows that somatostatin analogues may be safe in acromegalic patients with pre-existing diabetes. and 12% 6 of patients. The most frequently reported local adverse reactions were injection site pain (4.1%) and injection site mass (1.7%).
These local signs did not decrease the efficacy of the drug. 6 Other adverse events reported were sinus bradycardia (3%), hypertension (5%) and anaemia (3%). 6 As lanreotide treatment may decrease heart rate, the use of concomitant bradycardia-inducing agents such as beta-adrenoceptor antagonists may result in an additive effect and careful follow-up is necessary. Limited data suggest that lanreotide
Autogel is as well tolerated as octreotide LAR and there were no significant differences in the incidence of gastrointestinal signs. 41 Local adverse events occurred less frequently with lanreotide Autogel treatment than with octreotide LAR.
Dosage and Administration
Lanreotide Autogel comes in a long-acting aqueous-gel formulation that is administered via deep subcutaneous injections and provides consistent drug release. 42 The product is volume-dependent and not concentration-dependent, with volumes ranging from 0.3-0.5cc for delivery of the 60, 90 and 120mg doses. It is provided in a ready-to-use pre-filled syringe, which obviates the need for drug reconstitution prior to administration. This advantage enables self-administration or partner administration of the drug. A recent study by Salvatori et al. 43 found that 100% of patients or care-givers/partners were able to inject lanreotide Autogel correctly and no patient reported a preference to receive the injection by a healthcare professional. Consequently, the majority of these patients preferred lanreotide Autogel over octreotide LAR for future use. Similar results were previously reported by Bevan et al.
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Treatment Strategies
There are two main strategies on how to start the treatment.
According to the first one, treatment-naïve patients receive 60mg
once every 28 days. After three months, the dose is individualised according to the patient's response -it either remains stable or is gradually increased first to 90 and then to 120mg. The other possibility is to start with 90mg every 28 days for three months and adjust the dose thereafter. It is generally advised to regularly adjust the dose in relation to serum IGF-I and GH levels in order to obtain the best effect on disease activity at the lowest dose.
Usually, with continuing long-term treatment, the dose requirement progressively decreases. 45 Whenever acromegaly is well controlled, there are two options: reduce the actual dose or prolong the interval between injections. With lanreotide Autogel, the time interval between injections can often be increased to six to eight weeks without loss of efficacy, thereby improving the subject's comfort and reducing the cost of treatment. 46 In pharmacokinetic studies with lanreotide Autogel, significant levels were still found eight weeks after drug administration. 47, 48 Due to the wide therapeutic window of lanreotide, it is not necessary to alter the dose in hepatic or renal impairment or in the elderly.
Similarly, there are no reports of other drugs affecting the metabolism of somatostatin analogues.
There is limited experience with lanreotide Autogel at doses higher than those presented in product monographs, i.e. more than 120mg every 28 days. Only recently, Wuster et al. 49 presented data of two patients who required 180mg every three weeks to achieve or maintain their initial response. This high dose was given for three months in one patient and six months in the other without any unexpected adverse events.
To date, it is unknown whether somatostatin analogues may also provoke long-lasting disease remission after drug discontinuation, similarly to the definitive cure of prolactinomas frequently induced by dopamine agonists. The recent study by Ronchi et al. 50 is the only one that challenges the concept that therapy with somatostatin analogues is a lifelong requirement. The authors demonstrated remission in five patients out of 27 more than 12 months (median 24 months) after the discontinuation of chronic somatostatin analogue therapy.
To avoid life-long administration of somatostatin analogues, we have adopted a strategy to irradiate all adenoma remnants after surgery by Leksell gamma knife if <2.5cm in diameter and not touching the optic pathway. 51 Similarly, with the same conditions we have irradiated adenomas intended to be treated with pharmacological primotherapy.
Consequently the pharmacological therapy, mostly with somatostatin analogues, was limited to the interval between irradiation and normalisation of IGF-I levels. The mean interval to IGF-I normalisation was 4.5 years. 51 The side effects of Leksell gamma knife irradiation are rare. Hypopituitarism can be avoided by keeping the mean dose of irradiation given to pituitary tissue surrounding the adenoma below 15Gy and that to the distal infundibulum below 17Gy.
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Combination Treatment
Lanreotide Plus Cabergoline
The efficacy of lanreotide Autogel can be improved by co-treatment with cabergoline. In a study by Cozzi et al., 54 1.5-3.5mg cabergoline weekly normalised IGF-I in 42% of patients with acromegaly previously insufficiently controlled with lanreotide SR or octreotide LAR. The percentage suppression of GH and IGF-I was significantly greater with combined treatment in two other studies. 55, 56 Presumably, lanreotide
Autogel will accordingly profit from combination with cabergoline. The only concern with cabergoline is an increased risk of fibrosis development, particularly cardiac fibrosis with valvular defects. There are at least 10 studies demonstrating that the doses used in the treatment of prolactinomas do not cause serious valvular defects. 57 A
Pituitary Disorders Although relatively inexpensive and available as tablets, dopamine agonists only achieve normalisation of GH and IGF-I in a minority of patients. It is recommended they are only tried in selected patients with modestly elevated IGF-I levels and markedly elevated prolactin.
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Pegvisomant is generally well tolerated and achieves IGF-I normalisation in more than 95% of patients if the dose is appropriate.
Therapy is expensive, however, with the necessity of daily injections.
It is unable to prevent pituitary adenoma growth or cause adenoma shrinkage. Consequently, in many countries its use is recommended only in patients unresponsive to or intolerant of somatostatin analogue therapy. 
Future Perspectives
The present formulations of somatostatin analogues can be classified as second-generation effective GH-suppressive drugs. 
